Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report)’s stock price crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.00 and traded as high as $0.0003. Nascent Biotech shares last traded at $0.0003, with a volume of 7,500 shares changing hands.
Nascent Biotech Stock Performance
About Nascent Biotech
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation.
Featured Stories
- Five stocks we like better than Nascent Biotech
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- Unlocked: Elon Musk’s Next Big IPO
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
